Article

Investigating mechanisms of acquired drug resistance in Triple Negative Breast Cancer

2021-01-01

Abstract excerpt

Triple negative breast cancer (TNBC) is an aggressive, heterogenous, metastatic disease characterised by lack of oestrogen, progesterone and human epidermal growth factor 2 receptors. Due to the lack of druggable targets, chemotherapy remains the mainstay of treatment. Whilst patients initially respond to this therapy, they often relapse due to acquired drug resistance. Given the poor outlook, it is evident that a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0dfeb587-2fff-57ae-9388-ea44ec03d51b
DOI: 10.22024/unikent/01.02.88062

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Investigating mechanisms of acquired drug resistance in Triple Negative Breast CancerDOI 10.22024/unikent/01.02.88062Read

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read

Genome Instability and Pressure on Non-Homologous end Joining drives Chemotherapy Resistance via a DNA Repair Crisis Switch in Triple Negative Breast Cancer.Semantic proximity Read

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read

Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).Semantic proximity Read

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read

Resistance patterns in drug-adapted cancer cell lines reflect the complex evolution in clinical tumoursSemantic proximity Read

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair DeficiencySemantic proximity Read

Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancerSemantic proximity Read